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Background: Colombia began using artemisinin-based combination therapies for the treatment of uncompli-
cated Plasmodium falciparum malaria in 2006. It is necessary to implement resistance surveillance to anti-
malarial drugs in order to promptly detect changes in parasite susceptibility. The aim of this study was to
establish a susceptibility baseline of P. falciparum to artemether-lumefantrine using three monitoring tools.
Methods: Patients with uncomplicated malaria treated with artemether-lumefantrine underwent clinical and
parasitological follow-up over 28 days. Ex vivo test was performed using the microtest technique for chloro-
quine, arthemeter, dihydroartemisinin and lumefantrine. Pfmdr1 copy number and polymorphisms in Pfk13,
Pfatp6, Pfcrt and Pfmdr1 genes were analyzed.
Results: From a total of 150 screened patients, 49 completed follow-up for 28 days. All treated patients had
adequate clinical and parasitological responses. Parasitic clearance showed a drastic reduction of parasite bio-
mass at 24 hours and complete elimination at 48 hours. One hundred eleven isolates were processed, all
exhibited high susceptibility to artemisinins and a slight decrease in susceptibility to lumefantrine. No genetic
polymorphisms associated with resistance to artemisinin were found.
Conclusion: This study generated a susceptibility baseline in response to therapy with Coartem (artemether-
lumefantrine) with numerical reference values, which will allow data comparison with future studies to sys-
tematically monitor changes in the parasite and to provide an early alert to the health authorities.
Keywords: Artemisinin-based combination therapies (ACT), Colombia, Plasmodium falciparum, Polymorphisms, Resistance surveil-
lance, Therapeutic efficacy studies (TES)
Introduction
The current goal of the WHO Global Technical Strategy for
Malaria, 2016–2030 is to promote elimination of the disease,
especially in low transmission areas where resistance to antimal-
arial drugs has commonly originated.1 Despite the worldwide
reduction of malaria incidence and the number of fatal cases
registered in recent years, in the Greater Mekong subregion where
multidrug resistance has historically emerged, therapeutic effi-
cacy failures with artemisinin-based combination therapies (ACT),
such as artesunate-mefloquine, have increased.2 This situation,
so far unique to this area, has generated an epidemiological
alert on the global commitment to preserve the effectiveness of
artemisinin as a treatment for Plasmodium falciparum malaria.
In order to tackle the growing drug resistance,WHO has recom-
mended the implementation of regular surveillance programmes
employing tools such as therapeutic efficacy studies (TES),3 ex vivo
assays and molecular markers, to facilitate monitoring and con-
tainment.4 Additionally, it has been shown that measurement of
the parasitemia at 72 hours post-treatment with ACTs provides a
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simple and helpful screening method to detect changes in the pat-
tern of parasite susceptibility to artemisinins,5 becoming currently
one of the most widely used tests.
In Colombia, the Ministerio de Protección Social implemented
the use of ACTs in 2006. However, in 2007 antimalarial therapies
were unified with artemether-lumefantrine (ART-LUM) as the
adopted combination, and it still remains so today.6 Since the
introduction of ACTs in Colombia, studies have shown high effi-
cacy with artesunate-mefloquine7 and artesunate-amodiaquine,8
and low inhibitory concentrations 50 (IC50) for artemisinin deriva-
tives, such as artesunate9 and dihydroartemisinin10 (DHA) and
partner drugs as lumefantrine (LUM),10 suggesting appropriate
responses to ACTs. However, little information is available on the
therapeutic efficacy of ART-LUM combination or changes in the
parasites’ susceptibility or emergence of polymorphism associated
with artemisinins and lumefantrine resistance.
The aim of this study was to establish the behavior baseline
of P. falciparum populations circulating in Colombia and patients’
response to treatment, using the tools available for monitoring
the ART-LUM scheme in three sentinel sites. This response base-
line to Coartem (artemether-lumefantrine) in Colombia will be
the point of reference for subsequent measurements, allowing
data comparison and giving information about necessary future
changes.
Materials and methods
Geographic area and study population
Three sentinel sites were selected, taking into account the inci-
dence of P. falciparum malaria in Colombia from 2009 to 2012.
The sites were radically different in terms of the epidemiology
and transmission of P. falciparum; one site was set up in the
southern part of the Pacific region (Nariño), another was estab-
lished in the Atlantic region (Córdoba), and the third one in
southeastern Colombia (Guaviare) (Figure 1).
Therapeutic efficacy study
Sample size was determined according to an expected propor-
tion of 5% treatment failures in a population of infinite size,
with a 95% confidence interval and +4% accuracy. A total of
150 patients were included given the likelihood of a 20% patient
loss in a 28-day study. Since the epidemiological behavior of
malaria is different in the three chosen departments, the sam-
ple size was proportional to the number of expected P. falcip-
arum cases by locality; the estimated number of patients to be
included was therefore 38, 102 and 10 for Córdoba, Nariño and
Guaviare, respectively.
The selection of patients was conducted in five medical centers
or diagnostic facilities belonging to the public hospital network. The
selected patients met the following inclusion criteria: 1. ≥2 years of
age; 2. P. falciparum mono-infection and uncomplicated malaria; 3.
parasitemia between 250 and 50 000 trophozoites/μl; 4. absence
of chloroquine in the urine (negative Saker-Solomons test):13 5.
non-pregnant women with a negative pregnancy test (Xerion-Le
Belle, IMEX group, Bogotá, Colombia), 6. patients without any con-
comitant chronic illness. Patients with clinical evidence of severe
malaria were excluded. After the diagnosis by thick blood smears
and verifying mono-infection for P. falciparum, 4ml of venous blood
were taken from patients who agreed to participate voluntarily in
the study. Blood samples were collected in EDTA tubes and distribu-
ted as follows: 200 μl for microhematocrit, 400 μl were spotted on
Whatman grade 3MM filter paper (Brentford, United Kingdom) for
molecular study, and the remaining volume was used for ex vivo
study.
The patients included in the study received standard treat-
ment (day 0) according to the Colombian guide for antimalarial
treatment for uncomplicated P. falciparum malaria. The treat-
ment was 4 tablets twice a day for 3 days, with the number of
tablets (each containing 20mg ART and 120mg LUM) dependent
on weight.6 Patients were clinically supervised over 30 minutes by
the medical staff after administration of the first dose to check
for adverse reactions and then clinical and parasitological moni-
toring was conducted at days 1, 2, 3, 7, 14, 21 and 28. End-
points considered in this study were completion of the follow-up
period without treatment failure, loss to follow-up, withdrawal
from study, protocol violation and treatment failure. At the end
of 28 days, the patient response was evaluated according to the
classification system of response to treatment as treatment suc-
cess (adequate clinical and parasitological response-ACPR) and
Figure 1. Sentinel sites selected to carry out the study. Three sentinel
sites were chosen: one in Nariño department, which presents an annual
parasitaemia index (API=10.07) and an annual P. falciparum index
(AFI=9.58).11 In this department the samples were collected in two
municipalities: Tumaco (lat 1°49’N, long 78°52’W) and Francisco Pizarro
(lat 2°0.3’37”N, long 78°39´29”W). The second sentinel site was estab-
lished in Córdoba department (API=6.2; AFI=0.6)12 and the samples
were collected in the localities of Tierralta (lat 8°10’34”N, long
76°03’46”W) and Montelíbano (lat 7°59’13”N, long 75°25’30”W) and
the third site, in San José (lat 2°34’15”N, long 72°38’25”W), department
of Guaviare (API=6.4; AFI=0.9),12 where like Córdoba, there is a relatively
low incidence of P. falciparum malaria but also little information about
the behavior of the P. falciparum parasites in response to common anti-
malarials. The samples were collected in San José from November 2011
to May 2012, in Córdoba from July 2012 to June 2013, and in Nariño
from February to June 2013. In Tumaco, the Afro-Colombian population
predominates, whereas in Tierralta and Guaviare the populations are
principally Mestizo and indigenous.
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treatment failure (early treatment failure, late clinical failure, and
late parasitological failure).6 On day 3, the presence of parasites
was verified by thick blood smear and PCR.14
Ex vivo drug susceptibility assay
Pre-dose culture plates with antimalarial drugs
Parasites cultures in 96-well plates were tested with four anti-
malarial drugs: chloroquine (CQ), LUM, ART and DHA (Sigma
Aldrich, St. Louis, MO, USA) at the Colombian Instituto Nacional
de Salud, following the methodology described by Aponte
et al.10 For ART, a stock solution was made in ethanol. The con-
centration ranges of different drugs were 50–3200 nanomoles/
liter (nM) for CQ, 2.5–160 nM for LUM and 0.5–32 nM for ART and
DHA. Drug plate quality control was performed under the same
conditions used for samples, using the reference strains T4
(Thailand)15 and 3D7 (BEI Resources, Manassas, VA, USA),16
which are resistant and sensitive to CQ respectively. Afterwards,
the drug plates were transported under refrigeration (4–8°C) to
sentinel sites, stored under the same conditions and used within
two months of preparation.
Mark III schizonts maturation method (microtest)
Samples were processed at sentinel sites for a maximum of 6
hours after collection as previously described by Aponte et al.,10
adjusting the parasitemia from 0.005 to 0.1% (250–5000 tropho-
zoites/μl) with a 1.5% hematocrit. Two identical plates were pre-
pared for each sample and incubated at 37°C in a standard
atmosphere of 5% CO2, 5% O2 and 90% N2. The microtest was
stopped when the parasites reached at least 20% schizont mat-
uration in the positive control well (without drugs). All wells were
harvested as Giemsa-stained thick smears. The percentage of
schizonts was calculated as the number of schizonts (with three
or more nuclei) among 200 asexual forms using light microscopy
(1000X).17 The IC50, defined as the drug concentration at which
parasite maturation was 50% of that measured in drug-free con-
trol wells, was calculated using a non-linear regression model
with the software Hn-NonLin.18 Microtest reading quality control
was performed at the central laboratory (supplementary data).
Molecular markers
Four genes were analyzed taking into account that single
nucleotide polymorphisms and increased copy numbers in the
Pfmdr1 gene have been linked to changes in the parasite sus-
ceptibility and therapeutic failure to mefloquine, artesunate,
lumefantrine and quinine.19,20 Polymorphisms in Pfk13 (C580Y,
Y493H and R539T)21 and Pfcrt (K76T)22 genes were associated
with artemisinin and chloroquine resistance respectively, and
the S769N Pfatp6 mutation was associated with raised arte-
mether IC50.
23
DNA extraction
Plasmodium DNA was extracted from blood collected on filter
paper employing a commercial kit (QIAamp DNA Micro Kit, Qiagen,
Hilden, Germany) following the manufacturer’s instructions.
Detection of S769N allele in gene Pfatp6 and K76T allele in gene
Pfcrt
Allele detection was carried out by PCR-RFLP. The outer and
nested PCR for gene Pfatp6 was performed following the method-
ology reported by Adhin et al.24 and Ferreira et al.,25 respectively,
and for gene Pfcrt using the methodology described by Londono
et al.22(supplementary data). To determinate the allele in Pfatp6-
769, the digestion was made with the enzyme AflII (New
England Biolabs, Ipswich, MA, USA), while for Pfcrt-76 ApoI (New
England Biolabs) was used. The products of PCR-RFLP were sepa-
rated in agarose gels, stained with ethidium bromide (1mg/ml)
and visualized in the image analyzer UV Gel Doc XR (software
Quantity One 1-D, version 4.6.2, BioRad, Hercules, CA, USA).
Sequencing of K13-propeller, Pfatp6 and Pfmdr1 genes
Pfatp6 and Pfmdr1 genes were sequenced from field isolates with
the highest and lowest IC50 for artemisinins (ART and DHA) and
LUM, respectively. In order to determine polymorphisms in the
K13-propeller gene, samples from day 0 (from patients who were
followed until day 3) were amplified and sequenced following the
methodology reported by Ménard et al.26 The amplification of
Pfatp6 and Pfmdr1 genes was performed according to Ferreira
et al.25 and Imwong et al.,19 respectively. BioEdit Sequence
Alignment Editor, version 7.2.5 (Ibis Biosciences, Carlsbad, CA,
USA) and Codon Code Aligner, version 4.2.7, softwares were used
for bioinformatic analysis. Polymorphisms associated with
changes in susceptibility to antimalarials were evaluated in 14
positions of the Pfmdr1 gene and 29 of the Pfatp6 gene.
Estimation of Pfmdr1 gene copy number
Estimation of Pfmdr1 gene copy number was performed by real-
time PCR using SYBR Green DyNAmo HS kit (Thermo Fisher
Scientific Inc., Waltham, MA, USA). The primers used to amplify
the Pfmdr1 gene were described by Ferreira et al.20 and the pri-
mers for the normalizer gene (myosin C: PfMyoC) were designed
previously at the laboratory. The number of copies was deter-
mined by relative quantification using method 2−ΔΔCt,20 which
assumes that both target (Pfmdr1) and reference (PfMyo-C)
genes are amplified with efficiencies near 100% and within 5%
of each other. Once it was established that the target and refer-
ence genes have similar and nearly 100% amplification efficien-
cies, we determined the relative difference in expression level of
the target gene in different samples. All assays were performed
in duplicate in the thermocycler CFX96-BioRad detection system
(BioRad, Hercules, CA, USA).
The primers’ sequences and PCR programs for all molecular
assays reported here, are summarized in the supplementary
data.
Statistical analysis
All statistical analyses and generation of graphics were per-
formed using Stata/SE software, version 12 (Stata Corporation,
College Station, TX, USA). Ex vivo activity of each antimalarial
drug was expressed as the geometric mean of inhibitory con-
centration 50 (GM-IC50). The chi-square test was used to com-
pare categorical variables. For all statistical tests, a p-value
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equal to 0.05 was deemed significant. Fisher’s exact test (two-
tailed test) was used to analyze the statistical association
between SNPs and drug sensitivity. The statistical association
between Pfmdr1 copy number and sensitivity to LUM was
obtained by correlation coefficients.
Results
TES of artemether-lumefantrine combination
Of the 150 patients enrolled (Figure 2), only 49 (32.7%) com-
pleted the clinical and parasitological follow-up at 28 days; from
these 69.4% (34/49) were men, 69.4% (34/49) were Afro-
Colombians and 77.6% (38/49) were from urban areas in the
municipalities studied. The median age was 25 years, ranging
between seven and 75 years old, and 63.3% (31/49) of patients
were older than 20 years of age. On day 0 the range of parasit-
emia was between 70 and 54 800 trophozoites/μl with an aver-
age of 5880 trophozoites/μl, and seven patients (14.3%) had
gametocytes. Due to the reduction of malaria cases, a patient
with parasitemia greater than 50 000 trophozoites/μl was
included; this individual did not show any signs of complicated
malaria and had strict medical supervision. The distributions of
the above variables, according to the locality are shown in
Table 1.
The most common symptoms were: headache 98% (48/49);
chills 91.8% (45/49); sweating 85.7% (42/49); myalgias 85.7%
(42/49); anorexia 83.7% (41/49); fever 77.6% (38/49). Hematocrit
values ranged between 28 and 48%, with an average of 37.4%
and a median of 37%.
On physical examination 12.2% (6/49) patients had hepato-
megaly and 14.3% (7/49) splenomegaly (1 cm below the costal
margin left/right, respectively). All patients had negative count
for asexual parasites on the second day of monitoring, while
sexual parasitemia persisted until day 7, and the headache,
chills and fever until day 14, day 3 and day 1, respectively
(Table 1). The final outcome at 28 days of follow-up in these 49
patients was classified as ACPR (i.e. clinical and parasitological
resolution by the end of the follow-up period). No serious
adverse events were observed after the administration of the
first dose.
Evaluation of parasitemia at day 3 post-treatment
Ninety out of the 150 (60%) patients included in the study had
clinical and parasitological follow-up during days 1, 2 and 3.
Fifty four of them (60%) cleared the asexual parasitaemia at 24
hours and the remaining 40% (36/90) at 48 hours. PCR correc-
tion was made in 78/90 (86.6%) samples taken on day 3 with
negative results, except for two samples from Tumaco, which
were positive for P. falciparum. This result can be explained by
the presence of gametocytes in the thick blood smear.
Drug susceptibility assay
A total of 111 P. falciparum isolates included on day 0 were pro-
cessed by microtest (Figure 2). Only one (0.9%) of these sam-
ples (from Tumaco) did not achieve the required percentage of
schizont maturation and another sample was not evaluated for
chloroquine due to a technical failure. Geometric mean (GM)
(95% CI) of the IC50 of the total samples analyzed for each of
the drugs was 141.15 nM for CQ (95% CI 125.26 to 159.06),
7.07 nM for LUM (95% CI 6.29 to 7.96), 1.65 nM for ART (95% CI
1.44 to 1.91) and 1.18 nM for DHA (95% CI 1.03 to 1.35).
Overall, the results of the three sentinel sites showed low sus-
ceptibility to CQ in 64.2% (70/109) of isolates (Figure 3).
Although the studied populations have very good in vitro sus-
ceptibility to LUM, some of the analyzed isolates had a slight
decrease in susceptibility. Of the 110 isolates tested, 5.4% (6/
110) had IC50>20 nM for LUM, one of which came from Nariño,
two from Guaviare and three from Córdoba (Figure 3). In the
case of ART and DHA, over 90% of isolates had IC50<5 nM in
both cases (ART=91.9% and DHA=95.5%) (Figure 3). GMIC50 for
CQ was greater than 100 nM in the departments of Córdoba
and Nariño, being significantly higher in parasites isolated from
Figure 2. Flowchart describing the number of samples tested in each of the three studies. Patients enrolled and number of samples tested in the
in vivo, ex vivo and molecular components of this study.
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Nariño (p=0.02), whereas in Guaviare P. falciparum populations
susceptible to CQ were found (Table 2). In contrast with the
results for CQ, the IC50 for LUM did not differ significantly among
departments.
Molecular markers
Detection of S769N allele in Pfatp6 and K76T allele in Pfcrt
All isolates had the wild-type allele S769 in Pfatp6, while in Pfcrt
all isolates were found to be mutants (76T).
Detection of SNPs in the K13-propeller, Pfatp6 and Pfmdr1 genes
For sequencing Pfatp6, K13-propeller and Pfmdr1 genes, 17, 66
and 13 samples were included, respectively (Figure 2). No poly-
morphism was found in the K13-propeller gene in the region
coding for the propeller domain. For Pfmdr1 13 isolates were
sequenced, six with LUM IC50 above 20 nM (21.45 nM to
50.37 nM) and seven with the lowest IC50 (1.56 nM to 5.11 nM).
Fourteen polymorphisms previously reported were analyzed, the
D1246Y mutation was found in all isolates from Guaviare and
Córdoba, but it was not detected in Nariño isolates, while Y184F
and N1042D polymorphisms and the deletion of a repetition
ATT (located in a region of low complexity of the gene) were
found in all isolates analyzed. Additionally, a non-synonymous
mutation G406A was identified in one isolate from Córdoba with
a LUM IC50 of 24.3 nM (Table 3).
For Pfatp6 the eight isolates that had IC50>6 nm to ART or
DHA (6.33 nM to 12.17 nM) and nine isolates that had the low-
est IC50 for these drugs (0.5 nM to 3.48 nM) were chosen.
Twenty nine polymorphisms previously reported were analyzed,
only one synonymous mutation in the I898I position and the
deletion of codon 847 were identified in all samples (Table 4). In
addition, three polymorphisms were identified, which have not
been reported previously: a deletion of six bases ranging from
position 2350 to 2355 and two non-synonymous mutations at
positions S466N and V307D, the latter present in 37.5% (3/8) of
the samples had the highest IC50 for ART or DHA.
Pfmdr1 copy number estimation
Eighty one out of the 111 (73.0%) isolates were analyzable by
qPCR: 68% of them (55/81) had a single copy of the gene, 17%
Table 1. General demographic characteristics of the population included in the study of therapeutic efficacy and parasitological follow-up
Characteristics Study sites
Guaviare Cordoba Nariño
San José Montelíbano Tierralta Tumacoa
n (%) [95% CI] 4/49 (8.2) [2.3 to 19.6] 2/49 (4) [0.5 to 14] 7/49 (14) [6 to 27.2] 36/49 (73) [58.9 to 85.1]
Proportion of men (%) [95% CI] 2/4 (50) [6.8 to 93.2] 1/2 (50) [1.3 to 98.7] 6/7 (86) [42.1 to 99.6] 25/36 (69) [51.9 to 83.7]
Ethnicity n (%) [95% CI]
Indigenous 0 0 0 1/36 (3) [0.1 to 14.5]
Mestizo 4/4 (100) [39.8 to 100] 1/2 (50) [1.3 to 98.7] 2/7 (29) [3.7 to 71] 7/36 (19) [8.2 to 36]
Afro-Colombian 0 1/2 (50) [1.3 to 98.7] 5/7 (71) [29 to 96.3] 28/36 (78) [60.8 to 90]
Asexual parasitemia average on
day 0
3566 17007 4148 5856
Patients with gametocytaemia
on day 0: n (%)
2/4 (50) 1/2 (50) 1/7 (14) 4/36 (11)
b Previous episodes of malaria
n (%) [95% CI]
4/4 (100) [39.8 to 100] 2/2 (100) [15.8 to 100] 5/7 (71) [29 to 96.3] 36/36 (100) [90.2 to 100]
Negative thick film (asexual forms) n (%)
Day 1 1/4 (25) 0/2 4/7 (57) 26/36 (25)
Day 2 3/3 (100) 2/2 (100) 3/3 (100) 10/10 (100)
Persistence of gametocytes (n)
Day 1 1 NA NA NA
Day 2 1 NA NA NA
Day 3 NA 1 NA 3a
Day 7 NA NA 1 1
a Two patients from Tumaco without gametocytaemia on day 0 had gametocytes on other days: one patient on day 3 and the other on day 7,
without presenting sexual forms on other days of follow-up.
b Proportion of individuals who reported having suffered from malaria at least once prior to consultation (day 0).
Transactions of the Royal Society of Tropical Medicine and Hygiene
5 of 10
(14/81) presented two copies, 10% (8/81) three copies and
2.5% (2/81) four and five copies (Figure 4).
Discussion
Therapeutic efficiency study results demonstrated the efficacy
and safety of the ART-LUM combination in the studied popula-
tions, a situation that had been reported previously in Colombia
for other ACT.7,8 It is worth mentioning that reaching the sam-
ple size was quite difficult, due to the drastic reduction of cases
of P. falciparum malaria that occurred between 2011 and 2012,
which was 58% and 85% for Córdoba and Guaviare, respect-
ively.12 To improve patient recruitment, several strategies were
implemented, such as including individuals with parasitemia
levels below 250 trophozoites/μl, carrying out active search for
patients, extending the period of inclusion, and increasing the
number of locations. In addition, the high number of patients
lost during follow-up contributed to not achieving an adequate
sample size for TES.
The above facts demonstrate the need to implement a shor-
ter epidemiologic strategy, such as the clinical and parasito-
logical surveillance at day 3 post-treatment, considering that
artemisinin provides a particular advantage over other treat-
ments: rapid parasite clearance, which was demonstrated by
the absence of parasites by thick blood smears in 97% of
patients with parasitemia between 10 000 and 100 000 para-
sites/μl on day 3 post-treatment.5 Our work showed that on day
2, no patient had asexual positive parasitemia, which allows us
to recommend the implementation of clinical and parasito-
logical follow-up at day 2 and 3 post-treatment, in order to
detect early parasite clearance delays. This surveillance can be
Figure 3. Ex vivo susceptibility of P. falciparum isolates to four antimalarial drugs, stratified by sentinel sites. The susceptibility of the parasites to A.
chloroquine (CQ), B. lumefantrine (LUM), C. artemether (ART) and D. dihydroartemisinin (DHA) was determined by the schizonts maturation method
Microtest.
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routinely done by the national diagnostic network and would be
the simplest and fastest way to detect early changes in the sus-
ceptibility of the parasite to artemisinins. These results would be
the basis for proposing a TES, which will provide evidence for
therapeutic failure.
On the other hand, the percentage of sexual forms in the
population was nearly 20%, and Tumaco was the locality with
greater persistence of gametocytes post-treatment. Although
artemisinin has gametocytocidal effect on the early stages
(I–III), it does not prevent the transmission of the parasite to
the mosquito.34 This may suggest the common existence of
long-term infections and the need for the addition of gameto-
cytocidal drugs such as primaquine in the ACT scheme, as a
strategy to preserve the effectiveness of combination therapies
and to eliminate the likelihood of reservoirs. A previous epidemio-
logical study in Colombia highlighted the importance of using
primaquine, because the elimination of gametocytes is much
faster.7
In the ex vivo study, the evaluated isolates show high susceptibil-
ity to ART, LUM and DHA. However, it is noteworthy that for LUM,
27.2% (30/110) of the isolates had IC50 > 10nM, of which 1.8% (2/
110) were higher than 40nM compared to the results obtained by
Aponte et al. in 2006 and 2007, where the IC50 for LUM and ART
was less than 10nM for all isolates tested.10 In the case of artemisi-
nin derivatives, it was observed that more than 90% of isolates had
an IC50 < 5nM and only 1.8% (2/110) showed IC50 of 12.17 nM and
10.21nM for ART. These changes in susceptibility in vitro of some iso-
lates, which still have low IC50 according to the previously reported
Table 2. Ex vivo susceptibility of P. falciparum isolates from three sentinel sites in Colombia to four antimalarial drugs
Antimalarial Drug Guaviare Cordoba Nariño
GMIC50 (range) GMIC50 (range) GMIC50 (range)
n nM n nM n nM
Chloroquine 10 96.47 (50–246.36) 32 125.51 (50–512.98) 68 157.77 (50–914.84)
Lumefantrine 10 8.50(1.56–50.37) 33 8.05 (1.8–47.03) 68 6.47 (2.5–29.38)
Artemether 10 2.55 (1.06–7.17) 33 1.23 (0.47–7.23) 68 1.80 (0.5–12.17)
Dihydroartemisin 10 2.27 (0.88–7.51) 33 0.77 (0.27–5.12) 68 1.32 (0.5–7.58)
IC50: concentration of drug that is required for 50% inhibition in vitro; GMIC50: geometric mean of IC50; n: number of isolates tested; nM: nano-
moles/liter.
Table 3. Polymorphisms found in the Pfmdr1 gene in 13 Colombian isolates
Polymorphism Codon Nucleotide position Allele: frequency n (%) References
G406A G(GGA)/A(GCA) G1217C G: 12 (92)
A: 1 sample from TA (8)
Polymorphism not
reported previously
N86Y N(AAT)/Y(TAT) A256T N: 13 (100) Grobusch et al.27
E130K E(GAA)/K(AAA) G388A E: 13 (100) Veiga et al.28
Y184F Y(TAT)/F(TTT) A553T F: 13 (100) Veiga et al.28
G249 G(GGA/GGG) A747G G: 13 (100) Veiga et al.28
L327H L(CTT)/H(CAT) T980A L: 13 (100) Imwong et al.19
D587E D(GAT)/E(GAA) T1780A D: 13 (100) Imwong et al.19
N660 (deletion) N(ATT) 1978-1980 Deletion: 13 (100) Veiga et al.28
A750T A(GCA)/T(ACA) G2248A A: 13 (100) Veiga et al.28
S784L S(TCA)/L(TTA) C2350T S: 13 (100) Veiga et al.28
S1034C S(AGT)/C(TGC) A3106T S: 13 (100) Reed et al.29
N1042D N(AAT)/D(GAT) A3124G D: 13 (100) Reed et al.29
F1226Y F(TTT)/Y(TAT) T3677A F: 13 (100) Veiga et al.28
D1246Y D(GAT)/Y(TAT) G3735T D: 3 samples from TUM (23)
Y: 10 (77)
Reed et al.29
TA: Tierralta (Córdoba department); TUM: Tumaco (Nariño department). Polymorphisms with mutations when detected in the analyzed isolates,
have been highlighted in bold.
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thresholds related to resistance,23 reveal the importance of carefully
monitoring the in vitro response of parasite populations for artemisi-
nin and the partner drug, in order to enable timely identification of
changes that compromise such therapies. Recently, it was shown
that the ring-stage survival assay (RSA)35 can assess more accur-
ately in vitro behavior of parasites compared with conventional tests,
because it measures the survival rate of parasites in stage ring to a
short pulse with DHA (the active metabolite of artemisinin). One of
the limitations of the present study is the lack of information regard-
ing RSA, since this methodology was not available during the devel-
opment of the work. We are aware of the need to implement this
new trial in the country for routine surveillance and future resistance
studies.
Although chloroquine is not part of current therapeutic regi-
mens for P. falciparum malaria, it was used in Colombia until
2002. Interestingly, we observed an increase in the in vitro sus-
ceptibility to CQ of isolates circulating in Tumaco, in comparison
with isolates evaluated previously.10 Thus, the GMIC50 to CQ
using microtest in this locality was much higher previously
(2006/2007=319.2/341.5 nM vs 2013=157.77 nM). This observa-
tion suggests a re-expansion of wild-type parasite populations
compared with mutant parasites (K76T) in response to the
absence of CQ pressure. However, all isolates with IC50 for CQ
higher or lower than 100 nM had the 76T mutation in the Pfcrt
gene, indicating not only fixation of alleles but the existence of
other mutations in this gene or in other genes, which may be
Table 4. Analysis of polymorphisms in the Pfatp6 gene in 17 Colombian isolates
Polymorphism Codon Nucleotide position Allele: frequency n (%) References
V307D V(GTT)/D(GAT) T920A V: 13 (76)
D: 4 samples, 3 with ART IC50>6nM (24)
Polymorphism not
reported previously
S466N S(AGT)/N(AAT) G1395A S: 1 sample from SJG (6)
N: 16 (94)
Polymorphism not
reported previously
G786 – N787 (deletion) G(CAA)–N(GAT) 2350-55 Deletion: 1 sample from SJG (6) Polymorphism not
reported previously
R37K R(AGA)/K(AAA) G110A R: 17 (100) Jambou et al.30
I89T I(ATA)/T(ACA) T266C I: 17 (100) Jambou et al.30
W141V W(TGG)/V(GGG) T421G W: 17 (100) Jambou et al.30
H243Y H(CAT)/Y(TAC) C727T H: 17 (100) Menegon et al.31
L263E L(TTA)/E (GAA) TT791–2GA L: 17 (100) Uhlemann et al.32
L402V L(TTA)/V(GTA) T1204G L: 17 (100) Menegon et al.31
E431K E(GAA)/K (AAA) G1291A E: 17 (100) Menegon et al.31
A438D A(GCT)/D(GAT) C1313A A: 17 (100) Imwong et al.19
Y441Y Y(TAT/TAC) T1323C Y: 17 (100) Jambou et al.30
D443D D(GAT/GAC) T1329C D: 17 (100) Jambou et al.30
N465S N(AAT)/S(AGT) A1394G N: 17 (100) Miao et al.33
S538R S(AGT)/R(CGT) A1612G S: 17 (100) Jambou et al.30
T539I T(ACC)/I(ATC) T1614C T: 17 (100) Jambou et al.30
S557S S(TCT/TCA) T1671A S: 17 (100) Jambou et al.30
N569S N(AAT)/S(AGT) A1706G N: 17 (100) Jambou et al.30
T570T T(ACA/ACC) A1710C T: 17 (100) Jambou et al.30
Q574P Q(ACA)/P(CCA) A1721C Q: 17 (100) Jambou et al.30
A621S A(GCT)/S (TCT) G1861T A: 17 (100) Jambou et al.30
A623E A(GCA)/E (GAA) C1868A A: 17 (100) Jambou et al.23
A630S A(GCT)/S(TCT) G1890T A: 17 (100) Menegon et al.31
G639D G(GGC)/D(GAC) G1916A G: 17 (100) Jambou et al.30
E643Q E(GAA)/Q(CAA) G1927C E: 17 (100) Jambou et al.30
N683K N(AAT)/K(AAG) T2049G N: 17 (100) Menegon et al.31
S769N S(AGT)/N(AAT) G2306A S: 17 (100) Jambou et al.23
E847K/deletion E(GAG)/K (AAG) A2536G E : 1 sample from SJG (6), deletion: 16 (94) Imwong et al.19
I885I I(ATT/ATA) T2656A I: 17 (100) Jambou et al.30
I898I I(ATT/ATA) T2694A I (ATA): 17 (100) Jambou et al.30
I959I I(ATT/ATA) T2877A I: 17 (100) Jambou et al.30
I987I I(ATT/ATA) T2962A I: 17 (100) Jambou et al.30
ART: artemether; SJG: San Jose del Guaviare.
Polymorphisms with mutations, when detected in the analysed isolates, have been highlighted in bold.
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re-establishing susceptibility to the drug in an adaptive manner.
This has previously been demonstrated in isolates from French
Guiana, where the C350R mutation in Pfcrt is directly correlated
with an increased susceptibility to CQ.36
Polymorphisms found in Pfmdr1 and Pfatp6 had no significant
correlation (p>0.05) with the increase or decrease of the IC50 for
the drugs evaluated. A previous study with 15 isolates from dif-
ferent areas of the Colombian Pacific evaluated both SNPs and
copy numbers in Pfmdr1, finding only one copy of the gene.37 In
our study, we found that 32% (26/81) of the samples had more
than one copy of Pfmdr1. Nevertheless, a significant correlation
between copy number and IC50 values for the drugs tested was
not found. The increase in the number of copies of Pfmdr1 was
initially described in reference strains resistant to CQ and MQ as
W238 or clones of the Dd2 strain39 and is correlated widely with
low susceptibility to mefloquine. However, despite the fact that
lumefantrine belongs to the same group of arylamino alcohols as
mefloquine, no significant correlation was found, suggesting a
different mechanism of action with mefloquine. Additionally, it is
likely that a greater copy number of Pfmdr1 (≥5) is needed to
find a correlation with higher IC50 for DHA, as was demonstrated
by Cui et al.39 Ariey et al. found mutations in the K13-propeller
gene strongly associated with the response to artemisinin,21
which were evaluated in this study. None of the previously
reported mutations were found, which correlates with the
adequate therapeutic response and rapid parasite clearance.
In conclusion, the artemether-lumefantrine combination in
the three studied localities showed a high efficacy for the treat-
ment of uncomplicated P. falciparum malaria. This clinical out-
come, along with parasite clearance times on the second day
post-treatment and presence of parasites with wild-type geno-
type for the K13-propeller gene, constitutes the susceptibility
baseline that will serve as the starting point for futures studies
to systematically monitor changes in the behavior of parasites
to the current first-line treatment scheme for P. falciparum
malaria in Colombia.
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